[{"id":"e89ca099-43f8-4a01-ad40-1033ca8b724c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03286296","created_at":"2021-01-18T16:14:08.333Z","updated_at":"2024-07-02T16:36:57.394Z","phase":"Phase 1","brief_title":"LZM009 to Treat Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03286296","lead_sponsor":"Livzon Pharmaceutical Group Inc.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lipustobart (LZM009)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 08/21/2017","start_date":" 08/21/2017","primary_txt":" Primary completion: 03/06/2019","primary_completion_date":" 03/06/2019","study_txt":" Completion: 04/23/2019","study_completion_date":" 04/23/2019","last_update_posted":"2019-08-02"}]